In allergic disease, dendritic cells play a critical role in orchestrating immune responses to innate stimuli and promoting the formation of T helper 2 (T H 2) effector versus T-regulatory cells. Here, we review recent advances in our understanding of how current forms of immunotherapy modulate dendritic cell responses.
INTRODUCTION
Dendritic cells are professional antigen-presenting cells, which sit at the interface between innate and adaptive immunity where they help control the balance between inflammation and tolerance at mucosal sites. Following ligation of Toll-like receptors (TLRs), dendritic cells are an important source of proinflammatory cytokines, including interleukin (IL)-6 and tumor necrosis factor (TNFa), and type I interferons (IFNs) that are critical in eradicating pathogens. However, dendritic cells also contribute to adaptive immunity by regulating the differentiation of naïve T cells, and memory responses by antigen-specific T cells.
Several studies [1] [2] [3] have suggested that innate immune responses may be impaired in patients with allergic disease. Dendritic cells from patients with allergy show reduced IFNa secretion following treatment with TLR7 or TLR9 ligands, including viral stimulation [1, 4] . The development of innate immune function in allergic children also appears to be altered relative to their nonallergic peers [2] . Exactly how these alterations in innate immunity might contribute to exaggerated T helper 2 (T H 2) adaptive immune responses and allergic disease remains to be fully elucidated. Proinflammatory cytokines secreted by dendritic cells favor commitment to T H 2 phenotypes, whereas IFNa inhibits IL-4-driven T H 2 differentiation of CD4 þ T cells and destabilizes the T H 2 phenotype by suppressing expression of GATA3 [5] [6] [7] . In the setting of helminth infection and allergy, dendritic cells are believed to be activated by epithelial cell-derived thymic lymphopoetin (TSLP) via OX40 ligand to induce a T H 2-directed response [8] . However, normally dendritic cells capture proteins at mucosal surfaces and play a tolerizing role via their expression of inducible T-cell co-stimulator ligand (ICOSL), which induces the generation of T-regulatory (T reg ) cells [9] . Recently, dendritic cells from patients with allergic rhinitis and asthma were found to display impaired expression of ICOSL and thereby promote T cells to acquire T H 2 effector function, underscoring a potential role for this pathway in the pathogenesis of allergic disease [10 & ]. Two major types of immature dendritic cells are found in the peripheral circulation in humans:
hi , CD11c À plasmacytoid dendritic cells (pDCs), which express TLR7 and TLR9 and produce IFNa, and
þ myeloid dendritic cells (mDCs), which express TLR2 and TLR4 and produce IL-12 [11] . Dendritic cell subsets, especially of the mDC lineage and Langerhans cells, are also found in the oral mucosa and skin and can be further differentiated by the expression of CD207 (langerin), CD103, and epithelial cell adhesion molecule (Ep-CAM) [12] . Langerhans cells are believed to be of hematopoetic origin and differentiate from progenitor cells in response to transforming growth factor (TGFb) and TNFa [13] . Recently, it was shown that the stimulation of BDCA-1 RR BDCA-3 S circulating dendritic cells with thymic stromal lymphopoietin (TSLP) and transforming growth factor (TGFb) may be a novel pathway for Langerhans cell differentiation [14 & ]. Given the complex interplay between innate and adaptive immunity and the central role for dendritic cells in orchestrating this interaction, the ability of allergen immunotherapy to modulate allergic immune responses almost certainly involves alterations in dendritic cell function. The present review provides an update on the most recent publications related to the role of dendritic cells in immunotherapy for allergic disease.
EFFECT OF ORAL AND SUBLINGUAL IMMUNOTHERAPY ON DENDRITIC CELLS
Sublingual immunotherapy (SLIT) and oral immunotherapy (OIT) are two modalities currently being explored for treatment of food allergy, and SLIT is also increasingly being utilized as a therapy for rhinoconjunctivitis and asthma. With SLIT, an allergen preparation is held under the tongue for a period of time before swallowing, whereas OIT involves immediate ingestion of the allergen in a food vehicle.
A recent open-label, randomized trial of SLIT and OIT for the treatment of immunoglobulin E (IgE)-mediated cow's milk allergy evaluated dendritic cell innate and adaptive functions before, during, and after therapy [15 && ]. In this study, OIT and SLIT were found to produce differing effects on dendritic cell subsets, with OIT having the greatest effect on pDC function and SLIT on mDC responses. OIT appeared to partially correct the impaired pDC secretion of IFNa that has been reported in allergic populations. On the contrary, SLIT uniquely decreased TLR-induced IL-6 production by mDCs, and this latter finding appeared to be associated with the development of sustained unresponsiveness to milk. Notably, a similar enhancement in pDC responsiveness to TLR9 stimulation was observed in patients with allergy receiving subcutaneous immunotherapy for house dust mite and other aeroallergens [16] .
A second study [17 && ], which evaluated dendritic cell and other immunologic responses to peanut immunotherapy in school-aged children, found that OIT and SLIT suppressed T H 2 cytokine responses to peanut in dendritic cell-T cell cocultures. These changes were associated with reduced expression of CD40, human leukocyte antigen DR (HLA-DR), and CD86 expression on dendritic cells, and were most robust in mDC dendritic cell-T cell cultures from patients undergoing OIT. Interestingly, expression of CD80 demonstrated a reverse pattern of change, consistently with the opposing role of CD80 and
KEY POINTS
Sublingual and oral immunotherapies for food allergy elicit changes in dendritic cell innate and adaptive immune functions that may serve to reduce allergic inflammation and promote tolerance; in some cases, these changes are transient.
The role of the skin in induction of tolerance versus sensitization to allergens is complex and requires further study.
Recent evidence suggests that interactions among dendritic cells, regulatory T cells, and CD35
þ B cells are central to the immunosuppressive effects of immunotherapy.
Antigen-nonspecific modulation of innate immune responses may provide a novel means of augmenting the tolerogenic effects of immunotherapy.
CD86 in T-cell suppression and activation. The alterations in dendritic cell behavior induced by SLIT and OIT were not antigen-specific, as synonymous changes in dendritic cell responses were seen after stimulation with an irrelevant antigen (house dust mite). The changes were also not persistent, as most markers of immunologic suppression reversed after withdrawal from therapy and in some cases during ongoing maintenance therapy.
In a phase 1 single-site study [18 && ], immunologic responses from participants undergoing 24 months of peanut OIT were studied. The investigators found that T reg s from clinically 'tolerant' patients had greater suppressive function and higher levels of FOXP3 hypomethylation, and that dendritic cells isolated from patients posttherapy were capable of decreasing FOXP3 methylation in effector T cells. After a period off therapy, patients who lost clinical 'tolerance' demonstrated a reversion of methylation patterns at the FOXP3 locus in peanut-specific T reg s.
Collectively, these studies suggest that SLIT and OIT for food allergy are able to modulate the phenotype and function of circulating dendritic cells. Whether these effects are driven by the small quantities of allergen that reach the systemic circulation, or are an indirect consequence of the other immune changes exerted by immunotheraphy (e.g. changes in allergen-specific IgE or immunoglobulin G), requires further investigation.
ROLE OF DENDRITIC CELLS IN EPICUTANEOUS IMMUNOTHERAPY
Within the last few years, the skin has emerged as a novel route of allergen delivery in the form of epicutaneous immunotherapy (EPIT). Recent studies by Dioszeghy et al. [19, 20] have implicated a key role for dendritic cells in intact skin in mediating antigen uptake and the induction of tolerogenic responses during EPIT in mice. They found that ovalbumin (OVA) antigen was transported by dendritic cells in the superficial layers of the stratum corneum to draining lymph nodes, and that after EPIT, local and systemic responses were downregulated, as evidenced by a decrease in local allergic inflammation, systemic T-cell responses to OVA, and an increase in the number of splenic T reg cells. These T reg s appeared to persist even after EPIT has been discontinued, and they may protect against sensitization to new allergens. In additional studies of mice sensitized to milk [21 & ], milk-specific EPIT prevented subsequent sensitization to peanut and house dust mite via a T reg -dependent mechanism. EPIT was also associated with reduced expression of CD86 on allergen-activated dendritic cells.
In contrast to these findings, Tordesillas et al. [22 & ] recently found that application of peanut extract alone (no additional adjuvant) to intact skin of mice promoted allergic sensitization and the development of anaphylaxis upon subsequent oral exposure to peanut. The authors went on to show that dendritic cells purified from draining lymph nodes following epicutaneous exposure to peanut were sufficient for driving T H 2 responses to this allergen. Allergic responses to peanut were also dependent upon the innate cytokine, IL-33, because blockade of the IL-33 receptor following topical exposure mitigated T H 2 priming responses to peanut. Importantly, these observations were not true for all allergens. Topical application of less potent allergens, including milk and soy, failed to elicit an allergic response.
ROLE OF B CELLS IN PROMOTING TOLEROGENIC DENDRITIC CELLS
Although the T cell-dendritic cell relationship has received the most focus in efforts to understand how immunotherapy suppresses allergic inflammation or induces tolerance, another major cell population that has garnered interest is the B cell. Recent findings suggest that certain subpopulations of B cells, known as regulatory B cells, may play a critical role in supporting immunologic tolerance [23] .
In the field of immunotherapy, it was recently observed that human patients with egg allergy treated with allergen-specific immunotherapy appear to generate suppressor/regulatory B cells. Wu [24] found that, following treatment with immunotherapy, patients exhibited an increased frequency of CD27 þ CD35 þ memory B cells that had strong immunosuppressive properties. This B-cell population was found to produce TGFb, and when cocultured in the presence of OVA with immature dendritic cells induced the development of a tolerogenic TGFb þ dendritic cell population. Subsequent coculturing of these dendritic cells with T cells was able to induce a T reg population.
A role for CD35 þ B cells and dendritic cells in promoting tolerogenic changes in the context of immunotherapy has also been seen in murine studies. Zhang et al. [25 && ] sensitized mice with OVA to induce intestinal food allergy, and then treated the mice with OIT. They found that OIT induced the expansion of CD35 þ B cells, which promoted the differentiation of T reg s in the intestines, downregulated expression of CD80 and CD86 on dendritic cells, and suppressed ongoing allergic inflammation via expression of thrombospondin 1 (TSP1). In a second study [26] by the same group, the investigators further examined the relationship between B
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Innate and adaptive dendritic cell responses to immunotherapy Gorelik and Frischmeyer-Guerrerio tolerogenic responses. The authors found that by using a CD20 monoclonal antibody to deplete B cells, mice sensitized to OVA generated a lower frequency of TGFb þ tolerogenic dendritic cells, defined as CD11c Another recent study examined the effect of peanut OIT on the antigen-specific repertoire of B cells in humans. Patil et al. [27 & ] found that peanut OIT led to the expansion of peanut-specific memory B cells whose receptor repertoire was oligoclonal and somatically hypermutated. These changes occurred early during the course of treatment. Unrelated individuals were found to share similar peanutspecific B cell clones, consistent with convergent selection. Whether these shared clonal groups play a role in the clinical efficacy of immunotherapy requires further investigation.
OTHER EXPERIMENTAL APPROACHES THAT MAY MODULATE ADAPTIVE AND INNATE DENDRITIC CELL FUNCTION DURING IMMUNOTHERAPY
A number of studies have recently explored novel ways of modulating dendritic cell responses for potential application in allergen immunotherapy. Many of these approaches utilize antigen-independent strategies or pharmacologic methods of downregulating dendritic cell responses.
The generation of tolerogenic dendritic cells via incubation with glucocorticoids was investigated in latex allergy [28] . In this study, peripheral blood mononuclear cells were obtained from human patients with latex allergy, and dendritic cells were generated from isolated monocytes. Dendritic cells from allergic patients treated with dexamethasone (dx-DC) acquired an immature phenotype with low expression of MHCII and costimulatory molecules including CD40, CD80, and CD86. The dx-DCs exhibited reduced ability to present antigen, enhanced expression of IL-10 upon CD40L stimulation, and an increased propensity to promote development of latex-specific regulatory T cells. The authors concluded that dexamethasone-primed dendritic cells may be a useful tool in immunotherapy for latex allergic patients via their ability to downregulate allergen-specific T-cell responses.
Bakdash et al. [29] evaluated the potential for using calcidiol (25 dihydroxy vitamin D3) as a modulating agent to induce tolerogenic dendritic cells. The authors found that priming of maturing dendritic cells with calcidiol promoted generation of a population of IL-10 and IL-12-producing dendritic cells, which in turn induced the development of T cells that produced IL-10 and IFNg. The authors hypothesize that these T reg -like cells may promote a T H 1 and T reg immunologic skewing, and may be useful in counteracting a T H 2-directed immune response as is seen in allergic disease, and thus 'potentiate' allergen-specific immunotherapy.
Strategies for an antigen-independent immunotherapy were investigated by the use of mycobacterial antigens to modulate house dust mite (HDM)-induced allergic airway inflammation [30] . HDMsensitized mice (via subcutaneous injection) were treated with mycobacterial antigens via intramuscular injection at 2-week intervals. Mice were challenged with HDM both before and after treatment, and cellular and humoral markers of inflammation and airway hyperresponsiveness were assessed. Investigators found that mycobacterial antigens downregulated T H 2 responses and promoted IL-10 and IFNg production. Adoptive transfer of spleen cells from mice immunized with mycobacterial antigens recapitulated these changes in allergic recipients, but transfer from MyD88-deficient mice did not. In sum, the authors demonstrated that allergen-free immunotherapy can modulate innate immune responses in a way that reduces T H 2 adaptive immunity and allergic clinical responses in mice.
The use of bystander immunotherapy to generate tolerogenic dendritic cells was investigated by Navarro et al. [31] . In this model, mice were tolerized to OVA and subsequently sensitized to another antigen, Leishmania homolog of receptors for activated c kinase (LACK). Mice were then challenged to aerosols of LACK alone or OVA and LACK in concert. The authors found that airway inflammation and hyperresponsiveness decreased following cotreatment with both antigens. Protection required interaction between cytotoxic T-lymphocyte-associated protein-4 on T cells and ICOS on dendritic cells. Thus, in sum, exposure of the animal to a tolerogenic stimulus in concert with an antigen can provoke a bystander effect that results in decreased allergic inflammation to the antigen. The authors propose that this may explain the protective effects of allergen-specific immunotherapy against antigens that are different from those used during the desensitization.
CONCLUSION
Although dendritic cells have long been recognized to play a critical role in regulating innate and adaptive immune responses, several studies in recent years highlight a central role for these cells in driving the immunologic suppression that accompanies immunotherapy (Fig. 1) . In the setting of sublingual and oral immunotherapy for food allergy in school-aged children and adolescents, dendritic cells isolated from treated patients exhibited enhanced secretion of IFNa and reduced expression of proinflammatory cytokines following TLR stimulation. Dendritic cells also showed evidence of reduced activation as indicated by lower expression of co-stimulatory molecules, which was correlated with reduced expression of T H 2 effector cytokines in dendritic cell-T cell cocultures. At least some of these changes in dendritic cell phenotype and function are evident only transiently. The fleeting nature of the immunologic suppression in OIT and SLIT may not be surprising as only a minority of participants in these studies achieve long-lasting clinical tolerance. Whether more persistent changes would result if immunotherapy were begun earlier in life or were continued for longer periods remains to be seen, but recent studies suggest this may be the case [32] . Fascinating studies over the last few years examining the role of the skin in driving tolerogenic versus allergic responses to external antigens leave many questions unanswered, and further research into exactly how the skin can drive responses in either direction are clearly warranted. The role of the B cell in augmenting tolerogenic responses during immunotherapy represents another exciting area of investigation that deserves further attention. A greater understanding of how innate and adaptive immunity can be manipulated to promote tolerance in allergic disease will lead to novel and more effective immunotherapy strategies for these common conditions. Acknowledgements None. 
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